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DUODENAL CYTOCHROME B (CYBRD1) FERRIC REDUCTASE: FUNCTIONAL STUDIES IN CELLS 1 
F. Schlottmann, M. Vera Aviles, G.O. Latunde-Dada.  2 
 3 
King's College London, Diabetes and Nutritional Sciences Division, Faculty of Life Sciences 4 
and Medicine, Franklin-Wilkins Building, 150 Stamford Street, London, SE1 9NH, United 5 
Kingdom. 6 
Abstract 7 
Dietary non-heme ferric iron is reduced by the ferric reductase enzyme, duodenal 8 
cytochrome b (Dcytb), before absorption by the divalent metal transporter 1 (DMT1). A 9 
single nucleotide polymorphism (SNP rs10455 mutant) that is located in the last exon of 10 
Dcytb gene was reported in C282Y haemochrotomatosis HFE subjects. The present work 11 
therefore investigated the phenotype of this mutant Dcytb in Chinese hamster ovary (CHO) 12 
cells. These cultured cells were transfected with either wild type (WT) or the SNP vector 13 
plasmids of Dcytb. Ferric reductase assays were performed in Dcytb transgenic CHO cells 14 
using the ferrozine spectrophometric assay protocol. Furthermore, expression of the protein 15 
was confirmed by Western blot analysis. The Dcytb SNP rs10455 showed a gain-of-function 16 
capability since ferric reductase activity increased significantly (P<0.01) in the transgenic 17 
cells. Increased ferric reductase activity was found when CHO cells were pretreated with 18 
modulators of Dcytb protein expression. Although ferric reductase in endogenous CHO cells 19 
increased with deferoxamine or CoCl2, iron loading with ferric ammonium citrate (FAC) had 20 
the opposite effect. Taken together, the study reveals a gain-of-function phenotype for 21 
Dcytb rs10455 mutation that could be a putative modifier of colorectal cancer risk, with 22 
attendant variability in penetrance among human HFE C282Y homozygotes. 23 
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Introduction 3 
Duodenal cytochrome b (Dcytb) was identified and characterized1 as an iron-regulated ferric 4 
reductase localized primarily in the duodenal brush-border membrane1. The enzyme 5 
consists of 286 amino acids with six trans-membrane domains and is expressed in the brush 6 
border enterocytes.  Dcytb shares 45-50% sequence homology with cytochrome b561, a 7 
member of the family of oxidoreductases that is involved in ascorbate-mediated trans-8 
membrane electron transport.  Its expression has also been reported in the lungs1;2, human 9 
erythrocytes3 and in the brain4.  Dcytb functions as a reductase in the conversion of ferric to 10 
ferrous ion for apical membrane import1 by the divalent metal transporter (DMT1). Ferric 11 
iron reduction could also be affected by other metalloreductases (Steap proteins) and by 12 
non-enzymatic dietary reducing agents such as ascorbic acids 5.Unlike DMT16 and 13 
ferroportin 7, Dcytb lacks iron-response elements (IREs) even though it has been shown to 14 
be regulated by HIF2α and, indirectly, by hepcidin8;9.  Shah et al. demonstrated the 15 
functional binding of HIF2α to hypoxia response elements (HREs) upstream of Dcytb (sic. 16 
CYBRD1) promoter region8. Moreover, Dcytb and DMT1 expression was down-regulated by 17 
hepcidin during inflammation9. 18 
Iron loading penetrance of hereditary haemochromatosis (HH) was reported to be high as 19 
levels of serum ferritin levels, which serve as markers of iron stores, were elevated in 82% of 20 
males and 55% of females []. HH disease penetrance, however, was only about 28% (in 21 
males) and 1% (in females) for human subjects that are homozygous for the C282Y mutation 22 
in the HFE gene10. Environmental and genetic factors 11 are proposed as modifiers of the 23 
expression of disease symptoms in C282Y homozygous patients. Phenotypic concordance of 24 
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iron overload symptoms has been reported in C282Y homozygote siblings12;13. Moreover, 1 
data from both animal and human studies have revealed associations between genetic 2 
variants of some genes of iron metabolism and symptomatic indices of iron loading in HFE 3 
homozygotes14. Considerable genetic variation exists in the severity of iron loading in HFE 4 
hemochromatosis, and Dcytb polymorphisms which possibly explains the different 5 
symptomatic phenotypes. Notably, a significant association was found between a single 6 
nucleotide polymorphism (SNP) rs3806562, located in the 5'UTR of CYBRD1, and transferrin 7 
saturation15. Quite significantly, the association between SNP rs884409, located in the 8 
promoter region of Dcytb, was associated with reduced serum ferritin16. Dcytb SNP rs10455 9 
was also found in patients with iron overload who were also homozygous for a C282Y 10 
mutation in the HFE gene16. Dcytb rs10455, however, correlated positively with colorectal 11 
cancer17. As other potentially carcinogenic factors could result in iron overload, the precise 12 
and specific role of Dcytb rs10455 SNP was not evident in the phenotype of the disease in 13 
the patients studied16. In light of the above, it is imperative to study the functional activity 14 
of the rs10455 mutation in order to understand how it modifies iron overload phenotypes in 15 
human populations. The study therefore investigated ferric reductase activity of Dcytb SNP 16 
rs10455 mutation compared to that of the wild type in cultured transfected CHO cells. 17 
Materials and Methods 18 
Chemicals and reagents were obtained from Sigma-Aldrich or Merck (Dorset, UK) or from 19 
sources otherwise stated accordingly. 20 
Cells and culture conditions 21 
Chinese hamster ovary (CHO) cells were obtained from the American Type Culture 22 
Collection. Cells were cultured in Ham’s F12 Nutrient Mixture medium (Sigma-Aldrich) 23 
 4 
 
supplemented with 10% foetal calf serum, 4 mmol/l L-glutamine, 100 kU/L of penicillin, and 1 
100 mg/L streptomycin. Cells were maintained at 37°C in a humidified incubator containing 2 
95% air/5% CO2. Cells were trypsinised, plated in 12- or 24-well plates, and grown for 24 h to 3 
full confluency for the experiments. 4 
Transfection of cells 5 
 6 
Human Dcytb gene fragment of 873 base pairs was synthesized (Genscript, USA) and cloned 7 
into a pcDNA (+) 3.1 myc/his(1) mammalian expression vector by BamHI and HindIII. The 8 
sequence of the Dcytb insert and the flanking sequences of the cloning sites were verified. 9 
Moreover, restriction digestion revealed the correct size of the insert as the only band on 10 
agarose gel electrophoresis.  Cells were grown to 60–70% confluency andsubsequently 11 
transiently transfected with plasmid DNA using Fugene (Promega, USA) according to the 12 
manufacturer's protocol. Control cells were transfected with empty pcDNA 3.1 vector. 13 
Dcytb-expressing cells were selected with G418 and mixed colonies were used for the 14 
experiments. 15 
Ferric reductase activity in CHO cells 16 
CHO cells were grown to confluency in 12-well plates for ferric reductase assay. The assay 17 
buffer was prepared with 25 mmol/L 3-(N-morpholino)propanesulfonic acid (MOPS), 18 
25 mmol/L 2-(N-morpholino)ethanesulfonic acid (MES), 5.4 mmol/l KCl, 5 mmol/L glucose, 19 
140 mmol/L NaCl, 1.8 mmol/L CaCl2 and 800 µmol/L MgCl2. Additionally, 50 µmol/L FeCl3 20 
and 100 µmol/L nitrilotriacetic acid (NTA) and 200 µmol/L ferrozine were mixed and added 21 
to the MOPS assay buffer before incubation for 1 h at 37°C in the dark. Samples of assay 22 
buffer aliquots (200 µl) were read at 562 nm in the BioTek Synergy HT microplate reader. A 23 
ferrozine-based iron determination assay was performed (Reference needed here??). 24 
Standard curves were generated to convert the absorbance value into pmoles of iron 25 
reduced.  26 
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Endogenous reductase activity was measured using the protocol described above. 1 
Furthermore, cells were treated one day prior to the experiment with either 500 µmol/L 2 
(2,2,6,6-Tetramethylpiperidin-1-yl)oxyl (TEMPO), 100 µmol/L deferoxamine (DFO), 100 3 
µmol/L CoCl2, 100 µmol/L dehydroascorbic acid (DHA) or 100 µmol/L ferric ammonium 4 
citrate (FAC) following which ferric reductase assay was conducted. 5 
Western blot analysis 6 
CHO cells expressing WT, SNP Dcytb or empty plasmid were homogenized (in a buffer 7 
containing 0.1 mmol/L EDTA, 20 mmol/l KH2PO4, 135 nmol/L KCl and 1:200 (v/v) protease 8 
inhibitors at pH 7.4) with an Ultra Turrax (IKA, Staufen, Germany) homogenizer in (3 × 30 s 9 
pulses at full speed). The homogenate was centrifuged at 2000 rpm for 5 min. Following 10 
this,the supernatant was centrifuged for 1 h at 15,000 g to obtain the crude membrane 11 
fraction. Protein concentration was determined using Bio-Rad reagents (Bio-Rad, 12 
Laboratories, Hercules, CA, USA). Fifty (50) μg of membrane extracts were loaded onto a 13 
12% gel in a SDS-PAGE. The proteins separated were then transferred to nitrocellulose 14 
membrane using a Bio-Rad dry transfer apparatus (Trans-BlotR SD Dry Transfer Cell; Bio-15 
Rad, UK). Membranes were blocked with 5% milk for 1 h and probed with Dcytb Myc mouse 16 
antibody7 (Santa Cruz Biotechnology, USA), and, β-actin (Sigma, UK) antibodies diluted in 17 
TBS. Cross-reactivity was observed with peroxidase-linked anti-IgG by using SuperSignal 18 
West Pico (Thermo Scientific, USA). 19 
 20 
 Statistical analysis 21 
 22 
 Statistical differences between means were calculated using Student's t test in correcting 23 
for differences in sample variance. When multiple comparisons were necessary, 1-way or 2-24 
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way ANOVA was performed, using GraphPad Prism with Tukey's post hoc test. Differences 1 
were considered significant at p< 0.05. 2 
 3 
Results 4 
Dcytb SNP rs10455 5 
The Dcytb rs10455 SNP investigated in the current study is a Ser266Asp missense mutation 6 
located in the last exon of Dcytb WT gene and the amino acid serine is highly conserved 7 
from zebrafish to human (Fig 1a). Western Blot analysis of Dcytb WT and SNP rs10455 8 
protein expression in CHO cells is shown in Fig 1b. 9 
Dcytb SNP rs14055 increases ferric reductase activity in CHO cells  10 
CHO cells expressing Dcytb SNP rs10455 mutation exhibited significantly increased ferric 11 
reductase activity (Fig 2) compared to cells expressing Dcytb WT protein (p<0.01). 12 
Furthermore, both the SNP rs10455- and WT Dcytb-transfected CHO cells had significantly 13 
higher (p<0.001) ferric reductase activity than the control cells harboring the empty pcDNA 14 
plasmid only.  15 
Deferrioxamine, FAC and CoCl2 modulated ferric reductase activity in CHO cells 16 
Following this, transgenic CHO cells expressing both the SNP rs10455 and WT Dcytb were 17 
pretreated overnight with DFO, FAC, or CoCl2 (100 µmol/L) to simulate iron deficiency, iron 18 
loading or hypoxia. Ferric reductase activity was high in SNP rs10455 and WT Dcytb CHO 19 
cells than in cells with the empty plasmids (Fig 3). However, exposing cells to FAC overnight 20 
led to significantly reduced ferric reductase activity in all the three categories of samples 21 
(Fig 2). Consistently, CHO cells transfected with empty plasmid exhibited reduced ferric 22 
reductase activity when similarly exposed to the modulators of Dcytb expression. 23 
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Endogenous ferric reductase in CHO cells 1 
Endogenous reductase activities of untransfected CHO cells were also investigated after 2 
cells were treated with potent modulators of Dcytb expression. To this end, CHO cells were 3 
treated with FAC, DHA, TEMPO, DFO or CoCl2 and ferric reductase activity assays were 4 
compared against untreated cells (Fig. 4).  5 
Iron chelation by DFO resulted in a significant (p<0.05) increase of ferric reductase activity 6 
(Fig 4). Treatment of CHO cells with CoCl2, also enhanced ferric reductase activity, albeit to 7 
levels that were not significant statistically. However, iron loading of CHO cells with FAC 8 
reduced ferric reductase activity (p<0.001). Surprisingly, reductase activity was reduced in 9 
CHO cells exposed to either DHA (p<0.01) or the TEMPO radical (p<0.05) (Fig 4).  10 
Discussion 11 
Dcytb SNP rs14055 increases reductase activity 12 
Duodenal cytochrome b (Dcytb) reduces ferric to ferrous iron for transport by DMT1 from 13 
apical membrane of the enterocytes. Dcytb SNP rs10455 was identified in a sample 14 
population of human HFE subjects and the functional analysis of the SNP was investigated in 15 
cultured CHO cells in the current study. The SNP is a genomic A<G mutation in the last exon 16 
of Dcytb gene which is a Ser266Asn amino acid substitution. The amino acid locus in the WT 17 
protein is highly conserved from zebrafish to humans (Fig 1a), thus suggesting a functional 18 
essentiality. Hence, the evolutionary conservation of rs10455 polymorphism indicates 19 
functional significance of the disease phenotype. The expression of the protein of both the 20 
WT and SNP variant in CHO cells was confirmed by Western blot analysis (Fig 1b). To 21 
investigate the function of the SNP rs10455, ferric reductase was performed in transgenic 22 
CHO cells harboring the WT or mutant Dyctb gene. Empty plasmid was transfected into CHO 23 
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cells and served as the control. The data revealed a gain of function of ferric reductase 1 
activity of CHO cells expressing Dcytb SNP rs10455 protein (Fig 2) above the WT and control, 2 
this implying a surfeit of ferrous ion substrate for transport by DMT1 and possibly in HFE 3 
subjects, an accentuation of iron-loading indices. The hematological status of HFE subjects 4 
with the Dcytb SNP rs10455 was, however not presented in the study by Constantine11. 5 
Strikingly, Davies et al. reported a positive correlation between SNP rs10455 and colorectal 6 
cancer in a genome-wide gene association study17. The missense polymorphism in Dcytb 7 
was associated with colorectal cancer in UK populations of UK English, but not those of 8 
Scottish, ancestry17. Reaction cascades and substrate channeling of ferrous iron availability, 9 
ROS generation and the induction of carcinogenesis are well documented18. Body iron stores 10 
and dietary iron intake have both been positively correlated with risk of colon cancer in 11 
some studies19-21. Relevant to the current study, plasma iron biomarkers and gender, rather 12 
than HFE gene mutations, were found to increase the risk of colorectal cancer and the 13 
development of polyps in a cohort of patients22. Consequently, multivariate risk factors could 14 
potentially contribute to colorectal cancer and Dcytb SNP rs10455 is a candidate 15 
polymorphism that could be screened in colon cancer patients. 16 
In common with the findings in the current study, the loss-of-function phenotype of the 17 
Dcytb SNP rs884409 mutation was also associated11 with HFE subjects. However, this SNP is 18 
located in the promoter region of Dcytb, and HFE subjects with this polymorphism had lower 19 
serum ferritin than was found in the control group. Moreover, functional luciferase reporter 20 
assay of Dcytb SNP rs884409 revealed a reduced basal reductase activity by about 30%. The 21 
consequent reduction of Dcytb expression concomitantly lowered iron absorption, to confer 22 
protection against iron loading that typifies HFE patients. Two other Dcytb SNPs found in 23 
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exon 123 rs 17554 and rs 3806562 transferrin saturation [14]  were also reported to reduce 1 
the promoter activity in the gene16. These reports contribute to the reasons for varying 2 
(variable??) symptomatic or asymptomatic phenotypes in HFE genotype variants. 3 
Dcytb is upregulated in hypoxia and iron deficiency 4 
To further characterise the function of the Dcytb SNP rs10455, ferric reductase activity 5 
assays were conducted with modulators of Dcytb protein expression, notably the simulation 6 
of iron deplete, replete or hypoxia by FAC, DFO or CoCl2 respectively (Fig 3). Ferric reductase 7 
activity was enhanced (Fig 3) in CHO cells that were exposed to DFO (iron chelation) or CoCl2 8 
(chemical hypoxia). Ferric iron reduction increased by either 60% or 40% in mutant CHO 9 
cells that were treated respectively with DFO or CoCl2 (Fig 3). However, cells pretreated with 10 
iron loading exhibited a significant (P<0.05) 50% decrease  in ferric reductase activity (Fig 3). 11 
The effects of FAC, DFO and CoCl2 on ferric reductase activity were similar in the WT, SNP, 12 
untransfected categories as well as and in cells that were transfected with the empty 13 
plasmid (Figs 3 and 4).  14 
Dcytb mRNA levels was shown to be down-regulated by treating cells with iron and 15 
dehydroascorbic acid5. Moreover, Dcytb expression was down-regulated in iron overload 16 
conditions5;24 in the rat. The presence of dehydroascorbic in the assay medium, however, 17 
enhanced ferric reductase activity5. Dcytb is regulated by iron and hypoxia via the HIF2α5;25 18 
pathway. In normoxic conditions, iron- and oxygen-dependent HIF prolyl hydroxylases (PHD) 19 
mediate proteasomal degradation of HIF2α. However, during iron deficiency and hypoxia, 20 
PHD are inhibited so that HIF2α becomes stabilized and Dcytb expression is consequently 21 
enhanced8.The regulation of Dcytb by HIF2α was demonstrated in the enterocytes of 22 
mice8;25. Furthermore, expression of both Dcytb and DMT1 was shown to be enhanced by 23 
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HIF2α during the early stages of exposure to hypoxia26. As observed previously5;27, basal 1 
intrinsic ferric reductase activity could be high, variable in different cell types and, as seen in 2 
the current study, responsive to a number of modulating agents (Figs 3). Degeneracy and 3 
redundancy of ferric reduction ensue through both enzymatic and non-enzymatic processes 4 
in organs and tissues.  The seemingly low expression of endogenous Dcytb protein (Fig. 1b), 5 
in contrast to high basal reductase activity (Figs 2-4), attests to the potential activities of 6 
other ferric ion ‘reductases’ in the cells. Dcytb could, therefore, be redundant from reducing 7 
agents such as ascorbate, glutathione, cysteine or superoxide radical, and possibly by SDR2 8 
and Steap reductases as well. Significantly, however, Dcytb functionality is required 9 
particularly during conditions of enhanced iron absorption such as in hypoxia or cases of 10 
increased erythropoiesis5;28. 11 
In conclusion, this study provides evidence for a functional allelic association between Dcytb 12 
SNP rs10455 and ferric reductase activity in CHO cells. This gain-of-function polymorphism, 13 
might increase iron absorption in the gastrointestinal tract Future studies should now aim to 14 
elucidate underlying mechanisms of the SNP with relevance to the iron-loading phenotype 15 
of HFE subjects. 16 
 17 
Legends 18 
Figure 1a: SNP rs14055 is a highly conserved serine residue (red). (Adapted from 19 
http://web.expasy.org/variant_pages/VAR_038067.html). 20 
Figure 1b: Western blot of Dcytb WT and SNP rs10455 protein in CHO cells. CHO cell 21 
lysates were separated by electrophoresis and blotted onto a nitrocellulose membrane. 22 
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Lanes are Dcytb, 1, SNP rs10455 2 and Empty plasmid 3. Membrane was stripped and re-1 
probed with beta-actin antibody.  2 
Figure 2: Ferric reductase activity assay of Dcytb WT and SNP rs14055. The assay was 3 
conducted in CHO cells overexpressing Dcytb WT, SNP rs10455 or in cells transfected with 4 
the empty plasmid. Ferrous iron reduction was normalized with protein content of the cells. 5 
Data shown are means of n=4±SE. Significance levels were determined by the two sample t-6 
test for unequal variances (*p<0.05; (WT versus SNP rs10455) ** p<0.01; *** 7 
p<0.001(Empty versus WT/SNP rs10455). 8 
Figure 3: Reductase activity assay of Dcytb WT and SNP rs10455 pre-treated with DFO, FAC 9 
or CoCl2. CHO cells were overexpressing Dcytb WT (A), SNP rs10455 (B) or were transfected 10 
with the empty plasmid (C). Data shown are means of n=4±SE. Significance levels are shown 11 
for comparisons to untreated CHO cells as determined by the two sample t-test Empty 12 
versus WT/SNP (*** p<0.001) for DFO, CoCl2 and FAC  13 
Figure 4: Endogenous reductase activity assay of CHO cells. Untransfected cells were pre-14 
treated with 100 µmol/L FAC, 100 µmol/L DHA, 500 µmol/L TEMPO, 100 µmol/L DFO or 100 15 
µmol/L CoCl2 one day prior to the assay. Ferrous iron reduction was normalized with protein 16 
content of the cells. Data shown are means of n=4±SE. Significance levels are shown for 17 
comparisons to untreated CHO cells as determined by the two sample t-test for unequal 18 
variances.). Untreated versus WT (FAC, p<0.001, DHA, p<0.005, Tempo, p<0.005,  DFO, 19 
p<0.005, and CoCl2 p<0.005. 20 
Figure 5: Schematic representation of the physiological mechanism of non-haem iron 21 
absorption. Vectorial transport from the apical membrane in the small intestine into 22 
systemic circulation. Dcytb: Duodenal cytochrome b; DMT1: Divalent metal transporter 1; 23 
HCP1: Heme carrier protein 1; HO-1: Heme oxygenase 1; Hp: Hephaestin; LIP: Labile iron 24 
pool (Drawn by Christine Fischer, 2017). 25 
 26 
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Human 246 RGSMPAYSGNNMDKS---DSELNSEVAARKRNLALDEAGQRSTM 286 
 
Mouse 247 EGAIAISSAHSMDAADPADAESSSEGAARKRTLGLADSGQR 287 
 
Rat 246 EGAIAISSAHNMDAA---DAELSSEGAARKRTLGLVDTGQR 283 
 
Xenopus laevis 245 EGS-TITDCSNTEKS---DVELNSE-AARKRILKLDEAGQR 280 
 
Xenopus tropicalis 245 EGS-TITDCSNTEKS---DVELNSE-AARKRILKLDDAGQR 280 
 
Zebrafish 245 VGT---------------DMTTTS----------------- 253 
 
Figure 1a  SNP rs10455 affects a highly conserved serine residue (red). (Adapted from 
http://web.expasy.org/variant_pages/VAR_038067.html 
 
 
 Total length of Dcytb (aa) Position of conserved S 
Human 286 266 
Mouse 290 270 
Rat 286 266 
Xenopus laevis 283 264 
Xenopus tropicalis 283 264 
Zebrafish 253 253 
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